Should You Scoop Up Shares of 23andMe?
23andMe (ME) saw its shares slump in price after it reported its fourth-quarter earnings results last month. However, given the company’s multiple FDA authorizations for over-the-counter genetic health risk reports, would it be worth scooping up its shares now? Read on, let’s find out. shutterstock.com – StockNews 23andMe Holding Co. (ME) in Sunnyvale, Calif., is…